Vcanbio Cell & Gene Engineering Corp Rule of 40
The Rule of 40 of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 12, 2026 is 5.28 %. In the previous year, Rule of 40 was 8.29 % — a change of -36.35% (lower).
Get this data via API
Financial Data API
Rule of 40
5.28 %
YoY
-36.35%
Last updated:
Rule of 40 of Vcanbio Cell & Gene Engineering Corp is 2025 5.28 % . Rule of 40 of Vcanbio Cell & Gene Engineering Corp was 2024 8.29 % . It decreases by -36.35% lower compared to the previous year.
The Vcanbio Cell & Gene Engineering Corp Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
3.32 CNY
Jan 1, 2019
13.30 CNY
Jan 1, 2020
-11.92 CNY
Jan 1, 2021
30.73 CNY
Jan 1, 2022
11.31 CNY
Jan 1, 2023
10.49 CNY
Jan 1, 2024
8.29 CNY
Jan 1, 2025
5.28 CNY
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 5.28 % | -36.35% | |
| 8.29 % | -20.92% | |
| 10.49 % | -7.24% | |
| 11.31 % | -63.20% | |
| 30.73 % | -357.71% | |
| -11.92 % | -189.66% | |
| 13.30 % | +300.63% | |
| 3.32 % | -94.68% | |
| 62.39 % | +121.13% | |
| 28.21 % | -66.52% | |
| 84.28 % | — |
Access this data via the Eulerpool API
Vcanbio Cell & Gene Engineering Corp Stock analysis
What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Rule of 40 of Vcanbio Cell & Gene Engineering Corp is 5.28 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
Quality — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth